Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer

Bibliography

• What are the key statistics about prostate cancer? 2014. Available from: http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics [Last accessed 4 October 2014]
   Google Scholar
• SEER Cancer Statistics Factsheets: Prostate Cancer. National Cancer Institute. Bethesda, MD; 2014. Available from: http://seer.cancer.gov/statfacts/html/prost.html [Last accessed 4 October 2014]
   Google Scholar
• Pagliarulo V, Bracarda S, Eisenberger MA, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012;61:11-25
   PubMed Web of Science ®Google Scholar
• Bluemn EG, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol 2012;24:251-7
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer (Version 4.2013) 2013. Available from: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf [Last accessed 4 October 2014]
   Google Scholar
• Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24:3984-90
   PubMed Web of Science ®Google Scholar
• Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 2011;17:3876-83
   PubMed Web of Science ®Google Scholar
• Mohler JL, Titus MA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res 2011;17:5844-9
   PubMed Web of Science ®Google Scholar
• Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol 2012;4:167-78
   PubMedGoogle Scholar
• Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025-33
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005
   PubMed Web of Science ®Google Scholar
• Kluetz PG, Ning YM, Maher VE, et al. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2013;19:6650-6
   PubMed Web of Science ®Google Scholar
• Janssen Biotech Inc. ZYTIGA_ (abiraterone acetate) tablets: prescribing information. 2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202379s007lbl.pdf [Last accessed 5 October 2014]
   Google Scholar
• Nemes A, Tomuleasa C, Kascso G. The androgen receptor remains a key player in metastatic hormone-refractory prostate cancer. Implications for new treatments. J BUON 2014;19:357-64
   PubMed Web of Science ®Google Scholar
• Bastos DA, Dzik C, Rathkopf D, et al. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer. Oncology (Williston Park) 2014;28:693-9
   PubMed Web of Science ®Google Scholar
• Grist E, de Bono JS, Attard G. Targeting extra-gonadal androgens in castration-resistant prostate cancer. J Steroid Biochem Mol Biol 2015;145:157-63
   PubMed Web of Science ®Google Scholar
• Mohler JL, Gregory CW, Ford OH3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8
   PubMed Web of Science ®Google Scholar
• Holzbeierlein J, Lai P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27
   PubMed Web of Science ®Google Scholar
• Chang KH, Li R, Kuri B, et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 2013;154:1074-84
   PubMed Web of Science ®Google Scholar
• Potter GA, Barrie SE, Jaman M, et al. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995;38:2463-71
   PubMed Web of Science ®Google Scholar
• Vasaitis TS, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol 2011;125:23-31
   PubMed Web of Science ®Google Scholar
• Zobniw CM, Causebrook A, Fong MK. Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol 2014;6:97-105
   PubMedGoogle Scholar
• ZYTIGA (abiraterone acetate) tablets: prescribing information. 2013. Available from: http://www.zytiga.com/sites/default/files/pdf/full_product_information.pdf [Last accessed 5 October 2014]
   Google Scholar
• Yap TA, Carden CP, Attard G, et al. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 2008;8:449-57
   PubMed Web of Science ®Google Scholar
• Li R, Evaul K, Sharma KK, et al. Abiraterone inhibits 3beta-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res 2012;18:3571-9
   PubMed Web of Science ®Google Scholar
• Yang LP. Abiraterone acetate: in metastatic castration-resistant prostate cancer. Drugs 2011;71:2067-77
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:1481-8
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-71
   PubMed Web of Science ®Google Scholar
• Centocor Ortho Biotech Inc. Zytiga™ (abiraterone acetate) oral tablets: US prescribing information 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf [Last accessed 5 October 2014]
   Google Scholar
• European Medicines Agency. ZYTIGA 250 mg tablets: summary of product characteristics. 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002321/WC500112858.pdf [Last accessed 5 October 2014]
   Google Scholar
• Janssen-Cilag Ltd. Zytiga (abiraterone acetate) 250mg tablets: summary of product characteristics. 2013. Available from: http://www.medicines.org.uk/EMC/medicine/24976/SPC/Zytiga+250+mg+tablets/ [Last accessed 5 October 2014]
   Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Smith R, de Bono JS, et al. Updated interim analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (OCU-AA-302). Eur Urol 2014;66:815-25
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer [Abstract]. Ann Oncol 2014;25:255
   Google Scholar
• Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double- blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Lubeck DP, Mehta SS, et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003;170:S21-5
   PubMed Web of Science ®Google Scholar
• Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8:162-200
   PubMed Web of Science ®Google Scholar
• Longo DL. New therapies for castration- resistant prostate cancer. N Engl J Med 2010;363:479-81
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, A’Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8
   PubMed Web of Science ®Google Scholar
• Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Cli Oncol 2010;28:1489-95
   PubMed Web of Science ®Google Scholar
• Jacoby DB, Williams M. Differential effects of galeterone, abiraterone, orteronel, and ketoconazole on CYP17 and steroidogenesis. ASCO Meeting Abstr 2013;31:184
   Google Scholar
• Taplin ME, Chu F, Morrison JP, et al. ARMOR1: safety of galeterone (TOK-001) in a phase 1 clinical trial in chemotherapy naive patients with castration resistant prostate cancer (CRPC) [Abstract]. AACR Annual Meeting 2012;CT-07
   Google Scholar
• Stein MN, Patel N, Bershadskiy A, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl 2014;16:387-400
   PubMed Web of Science ®Google Scholar
• Janssen Research & Development LLC. A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Patients With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC). 2014. Available from: http://clinicaltrials.gov/show/NCT01715285 [Last accessed 5 October 2014]
   Google Scholar
• Parker CC, Sydes MR, Mason MD, et al. Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. BJU Int 2013;111:697-9
   PubMed Web of Science ®Google Scholar
• Dendreon. A randomized, open-label, Phase II trial of sipuleucel-T with concurrent versus sequential administration of abiraterone acetate plus prednisone in men with metastatic castrate resistant prostate cancer (mCRPC). 2014. Available from: http://clinicaltrials.gov/show/NCT01487863 [Last accessed 5 October 2014]
   Google Scholar
• University of washington abiraterone acetate, prednisone, and leuprolide acetate or goserelin before and during radiation therapy in treating patients with localized or locally advanced prostate cancer. 2014. Available from: http://clinicaltrials.gov/show/NCT01023061 [Last accessed 5 October 2014]
   Google Scholar
• Duke university abiraterone, radiotherapy and short-term androgen deprivation in unfavorable localized prostate cancer. 2014. Available from: http://clinicaltrials.gov/show/NCT01717053 [Last accessed 5 October 2014]
   Google Scholar
• Memorial Sloan-Kettering Cancer Center 3-arm Study of Abiraterone Acetate Alone. Abiraterone acetate plus degarelix, a GnRH antagonist, and degarelix alone for patients with prostate cancer with a rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy. 2014. Available from: http://clinicaltrials.gov/show/NCT01751451 [Last accessed 5 October 2014]
   Google Scholar
• UNICANCER. Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery (CARLHA). 2014. Available from: http://clinicaltrials.gov/show/NCT01780220 [Last accessed 5 October 2014]
   Google Scholar
• Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17:5913-25
   PubMed Web of Science ®Google Scholar
• Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68:5469-77
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028-38
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Molina A, Li J, et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol 2013;31:2791-8
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Peng W, Kheoh T, et al. Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis 2014;17:192-8
   PubMed Web of Science ®Google Scholar
• Efstathiou E, Titus MA, Wen S, et al. Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC) [Abstract]. J Clin Oncol 2014;32:5s
   PubMed Web of Science ®Google Scholar